Survival and prognostic factors of oligometastatic non-small cell lung carcinoma: A single center experience

Introduction: In patients without targeted-mutations platinum-based chemotherapy is still current treatment method with a median survival rates of 8-11 months. Patients with single side oligo-metastatic disease should be consider for curative aggressive therapies for both primary and metastatic sides for better survival (NCCN 2016). Method Totally 29 oligo-metastatic NSCLC (16 adenocarcinoma, 13 non-adenocarcinoma) patients was evaluated retrospectively. In addition to surgery concurrent and sequential chemo-radiotherapy (CRT) were accepted as curative approach. Results: 25 male and 4 female with median age 58. There were 9 patients in each group of surgery and chemoradiotherapy (CRT). Metastasectomy, SBRT and radiotherapy was performed for metastasis. Rest of individuals had systemic chemotherapy or supportive care. Median follow-up time was 14.7 months. Median overall survival (OS)was 35 months, progression-free survival (PFS) was 15.7 and survival after first progression (SAFP) was 15.7 months (Figure1 ). OS=37.4 months for surgery, 33.5 months for CRT, p>0.05, PFS=16.3 months for surgery, 15.6 months for CRT, p>0.05 and SFAP=17.2 months for surgery, 12.9 months for CRT, p>0.05. In univariate cox-regresson analyses increase in cT staging (23 months for T1-2 and 6.5 months for T3-4, p=0.01; HR (95%CI): 7.9 (1.5-41.2) and existance of treatment toxicity (19.3 vs 0.6 months, p=0.03; HR (95%CI): 8.46 (1.14-62.6) was related to poor SAFP (Figure 2). Synchronous type showed higher OS than metachronous (35.6 vs. 25.2 months p>0.05). Conclusion: Even oligometastasis means stage 4 disease in lung cancer, radically treated patients can have more than 2 years survival.